Ablynx N.v.

Ucb Pharma, S.a.

Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg

Regorius Leurs

Peter Vanlandschoot

Martine Smit

Johannes Joseph Wilhelmus De Haard

Michael John Scott Saunders

Catelijne Stortelers

Christophe Blanchetot

Francis Descamps

Philippe Van Rompaey

Pascal Gerard Merchiers

Sven Jähnichen

Maria Gonzalez Pajuelo

David Andre Baptiste Maussang-Detaille

Dominique Schols

Peter Verheesen

Maarten Van Roy

Patrice Talaga

Sylvain Celanire

Frederic Denonne

Maria Gonzalez

Hendrik Adams

David Andre Baptiste Maussang Detaille

Rogier Adriaan Smits

Iwan Jozef Philomena De Esch

Henkdrik Timmerman

Florence Lebon

Johannes Joseph De Haard

Michael John Saunders

Sven Jaehnichen

David André Baptiste Maussang-Detaille

The present invention relates to particular polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the present invention provides immunoglobulin single variable domains inhibiting CXCR7 mediated tumor growth.

Biological materials related to CXCR7

The present invention relates to amino acid sequences that are directed against (as defined herein) human cellular receptors for viruses and/or bacteria such as e.g. Nanobodies specifically recognizing hCD4, hCXCR4, hCCR5, hTLR4, human alphaV integrin, human beta3 integrin, human beta1 integrin, human alpha2 integrin, hCD81, hSR-BI, hClaudin-1, hClaudin-6 and hClaudin-9, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. Amino acid sequences of the present invention may be used to prevent human cell entry of HIV, HCV, adenoviruses, hantavirus, herpesvirus, echo-virus 1 and others.

Amino acid sequences directed against cellular receptors for viruses and bacteria

The present invention relates to particular polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes.

The present invention relates to amino acid sequences that are directed against G-protein coupled receptors (GPCRs), as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. The invention also relates to nucleic acids encoding such amino acid sequences and; to methods for preparing such amino acid sequences and polypeptides; to host cells expressing or capable of expressing such amino acid sequences or polypeptides; to compositions, and in particular to pharmaceutical compositions, that comprise such amino acid sequences, polypeptides, nucleic acids and/or host cells; and to uses of such amino acid sequences or polypeptides, nucleic acids, host cells and/or compositions, in particular for prophylactic, therapeutic or diagnostic purposes.

Amino acid sequences directed against GPCRS and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders

The present invention relates to amino acid sequences that are directed against (as defined herein) G-protein coupled receptors (GPCRs) and in particular to CXCR4 and CXCR7, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences (also referred to herein as 'amino acid sequences of the invention', 'compounds of the invention', and &#x201c;polypeptides of the invention&#x201d;, respectively). Furthermore, the invention provides a new method of making amino acid sequences that are directed against transmembrane protein, and in particular for multiple spanning transmembrane proteins for which the native conformation cannot be reproduced in other &#x201c;in vitro&#x201d; system (e.g. GPCRs in general).

Amino acid sequences directed against CXCR4 and other GPCRs and compounds comprising the same

The present invention relates to amino acid sequences that are directed against (as defined herein) human cellular receptors for viruses and/or bacteria such as e.g. NANOBODIES specifically recognizing hCD4, hCXCR4, hCCR5, hTLR4, human alphaV integrin, human beta3 integrin, human beta1 integrin, human alpha2 integrin, hCD81, hSR-BI, hClaudin-1, hClaudin-6 and hClaudin-9, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. The amino acid sequences may be used to prevent human cell entry of HIV, HCV, adenoviruses, hantavirus, herpesvirus, echo-virus 1 and others.

A compound of the formula (I) wherein X is CRor N; Y is CRor N; R, R, R, Rand Rare independently H, F, Cl, Br, I, or a hydrocarbon group which optionally contains one or more heteroatoms; Ris a heterocyclic group including one or more N atoms; R' is Ror NRRwherein R, Rand Rare each H or the same or different groups, including cyclic groups formed by Rand Rwith the N atom, of up to 20 C atoms and optionally including up to 3 further heteroatoms selected from N, O and S; or a pharmaceutically acceptable salt, ester or solvate thereof. 

Quinazolines and related heterocyclic compounds, and their therapeutic use

The present invention relates to compounds comprising an oxazoline or thiazoline moiety, processes for preparing them, pharmaceutical compositions comprising said compounds and their uses as H-receptor ligands, (I), wherein Ais CH C(CH) or N; Ris hydrogen or halogen; Ris (II); Ais O or S; Ris hydrogen, halogen, Calkyl or Calkoxy; Ris hydrogen, halogen, Calkyl, Calkoxy, trifluoromethyl or &#x2014;O&#x2014;(CH)n-NReach CHin &#x2014;O&#x2014;(CH)n-NR12b being optionally substituted by one or two Calkyl; Ris hydrogen or &#x2014;O&#x2014;(CH)&#x2014;NR, each CHin &#x2014;O&#x2014;(CH)&#x2014;NRRbeing optionally substituted by one or two Calkyl, and at least one of Rand Rshould be a &#x2014;O&#x2014;(CH)n-NRRgroup. 

Compounds comprising an oxazoline or thiazoline moiety, processes for making them, and their uses

Growing community of inventors

Amsterdam, Netherlands

Regorius Leurs